CRIS Current Research Information System

CATANI, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.485
EU - Europa 2.863
AS - Asia 1.778
AF - Africa 196
SA - Sud America 13
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.344
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.466
GB - Regno Unito 746
CN - Cina 546
SE - Svezia 546
IT - Italia 506
SG - Singapore 484
VN - Vietnam 412
DE - Germania 369
IN - India 199
IE - Irlanda 162
FR - Francia 111
RU - Federazione Russa 98
TG - Togo 74
UA - Ucraina 68
EE - Estonia 59
ZA - Sudafrica 52
BG - Bulgaria 49
JO - Giordania 46
CH - Svizzera 40
CI - Costa d'Avorio 36
FI - Finlandia 35
BE - Belgio 34
NG - Nigeria 24
TR - Turchia 24
CA - Canada 19
IR - Iran 19
ID - Indonesia 9
BR - Brasile 8
HK - Hong Kong 8
JP - Giappone 8
MY - Malesia 8
NL - Olanda 7
AU - Australia 6
ES - Italia 5
SC - Seychelles 5
AT - Austria 4
PL - Polonia 4
CL - Cile 3
CZ - Repubblica Ceca 3
GR - Grecia 3
LB - Libano 3
LT - Lituania 3
RO - Romania 3
TH - Thailandia 3
BD - Bangladesh 2
EG - Egitto 2
GH - Ghana 2
HR - Croazia 2
HU - Ungheria 2
IL - Israele 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CO - Colombia 1
CY - Cipro 1
GE - Georgia 1
MA - Marocco 1
PK - Pakistan 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
VE - Venezuela 1
Totale 9.344
Salva come PNG Salva come JPEG
Città #
Southend 663
Fairfield 535
Chandler 524
Singapore 417
Ashburn 371
Dong Ket 263
Woodbridge 237
Houston 226
Seattle 223
Wilmington 219
Cambridge 216
Ann Arbor 195
Santa Clara 177
Princeton 171
Dublin 162
Boardman 148
Bologna 106
Lomé 74
Nanjing 67
Westminster 66
Padova 56
Bremen 54
Redmond 50
Beijing 49
Sofia 49
Milan 47
Amman 46
Jinan 46
New York 43
Turin 42
Shenyang 41
Berlin 40
Abidjan 36
Helsinki 35
Brussels 34
Bern 33
Hyderabad 32
San Diego 31
Saint Petersburg 30
Florence 26
Jacksonville 24
Los Angeles 22
Abeokuta 21
Medford 20
Guangzhou 18
Nanchang 18
Burdur 17
Redwood City 17
Zhengzhou 17
Falls Church 16
Hebei 16
Changsha 15
Norwalk 14
Taiyuan 14
Fremont 12
Shanghai 12
Tianjin 12
Dearborn 11
Des Moines 11
Hangzhou 10
Boydton 9
Bühl 9
Jakarta 9
Monheim 9
Ningbo 9
Perugia 9
Toronto 9
Hefei 8
Jiaxing 8
Leawood 8
London 8
Rome 8
Kuala Lumpur 7
Kunming 7
Limidi 7
Mountain View 7
Paris 7
Tokyo 7
Zanjan 7
Andover 6
Munich 6
Olalla 6
Pune 6
Qingdao 6
San Francisco 6
Wenzhou 6
Abano Terme 5
Casalecchio di Reno 5
Frankfurt am Main 5
Harbin 5
Henderson 5
Kuban 5
Mahé 5
Shenzhen 5
Shijiazhuang 5
Winnipeg 5
Wuhan 5
Xi'an 5
Boston 4
Canzo 4
Totale 6.459
Salva come PNG Salva come JPEG
Nome #
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 200
A novel model of CCl4-induced cirrosi with ascites in the mouse. 186
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 174
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 169
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 160
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 158
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 156
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 155
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 150
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 150
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 147
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 145
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 145
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 145
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 145
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 143
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 143
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 140
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 137
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 137
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 133
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 129
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 128
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 128
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 126
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 124
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 123
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 122
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 118
Increased transcription of mitochondrial genes for Complex I in human platelets during ageing 117
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 117
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 117
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 116
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: a phase I clinical trial 115
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 114
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy 114
Stem cell mobilization and collection in patients with liver cirrhosis. 112
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 112
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 111
SuperB: A High-Luminosity Asymmetric e+ e- Super Flavor Factory. Conceptual Design Report 111
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function 111
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 110
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 108
null 107
The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis 107
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 107
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 106
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. 105
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 103
The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engrftment. 102
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 101
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 100
null 98
null 96
Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. 95
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 95
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 93
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 92
Platelet lysate enhances the therapeutic activity of Adipose Derived Mesenchymal stromal cells isolated from Crohn disease patients in a novel Mouse model of Colitis 92
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 91
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 91
The “vesicular intelligence” strategy of blood cancers 89
CD 133+ stem cells for the treatment of end stage liver disease. 87
The CD47 pathway is deregulated in human immune thrombocytopenia 86
null 86
INFLAMMATORY PATHWAYS IN THE BONE MARROW: ROLE OF TIMP-1 IN HEMATOPOIETIC STEM/PROGENITOR CELLS AND LEUKEMIA 85
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge 85
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 85
Low-dose methotrexate as treatment of myeloproliferative neoplasms: Proof of principle of clinical activity 84
Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product 79
CD133+ stem cells for the treatment of end-stage liver disease 74
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 72
null 68
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 66
CD133+ hematopoietic stem cells reinfusion in end-stage liver disease (ESLD): final results of a phase I clinical trial 66
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 64
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 62
SPONTANEOUS MOBILIZATIONOF BONE MARROW-DERIVED HEMATOPOIETIC AND ENDOTHELAIL PROGENITOR CELLS AFTER ORTHOTOPIC LIVER TRANSPALNTATION (OLT). 58
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 54
Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability 53
Reinfusion of highly purified CD133+ stem cells in patients with end-stage liver disease (ESLD): final results of a phase I clinical trial 46
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 43
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 40
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 40
The power of extracellular vesicles in myeloproliferative neoplasms: “Crafting” a microenvironment that matters 38
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 33
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis 30
Is there a gender effect in polycythemia vera? 26
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 26
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation 25
A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase 21
Ticlopidine in the treatment of thrombotic thrombocytopenic purpura: Report of two cases 19
Ascorbic acid for the treatment of chronic refractory idiopathic thrombocytopenic purpura (ITP) 13
Cancer procoagulant in acute non lymphoid leukemia: Relationship of enzyme detection to disease activity 12
Increased P-selectin plasma levels in patients with thrombotic thrombocytopenic purpura 12
Biological characterization of CD34+ cells mobilized into peripheral blood 11
Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides 11
Characterization of autotransplant-related thrombocytopenia by evaluation of glycocalicin and reticulated platelets 10
Biological characterization of CD34+ cells mobilized into peripheral blood 10
null 10
Totale 9.461
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.788
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.788
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.353 0 0 0 0 0 210 249 271 279 144 98 102
2020/20211.206 201 67 20 30 46 51 33 62 124 68 48 456
2021/20221.829 118 92 91 194 140 68 48 125 60 203 378 312
2022/20232.094 210 293 120 276 121 175 50 157 367 78 143 104
2023/2024601 48 96 41 75 53 126 27 33 15 41 22 24
2024/20251.256 120 265 205 213 344 109 0 0 0 0 0 0
Totale 9.640